Show simple item record

dc.contributor.authorAllison, KH
dc.contributor.authorHammond, MEH
dc.contributor.authorDowsett, M
dc.contributor.authorMcKernin, SE
dc.contributor.authorCarey, LA
dc.contributor.authorFitzgibbons, PL
dc.contributor.authorHayes, DF
dc.contributor.authorLakhani, SR
dc.contributor.authorChavez-MacGregor, M
dc.contributor.authorPerlmutter, J
dc.contributor.authorPerou, CM
dc.contributor.authorRegan, MM
dc.contributor.authorRimm, DL
dc.contributor.authorSymmans, WF
dc.contributor.authorTorlakovic, EE
dc.contributor.authorVarella, L
dc.contributor.authorViale, G
dc.contributor.authorWeisberg, TF
dc.contributor.authorMcShane, LM
dc.contributor.authorWolff, AC
dc.date.accessioned2020-01-28T12:29:24Z
dc.date.issued2020-05
dc.identifier.citationArchives of pathology & laboratory medicine, 2020, 144 (5), pp. 545 - 563
dc.identifier.issn0003-9985
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3499
dc.identifier.eissn1543-2165
dc.identifier.doi10.5858/arpa.2019-0904-sa
dc.description.abstractPURPOSE.—:To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS.—:A multidisciplinary international Expert Panel was convened to update the clinical practice guideline recommendations informed by a systematic review of the medical literature. RECOMMENDATIONS.—:The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose. Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive. However, the Expert Panel acknowledges that there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive. Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment. A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive. Additional strategies recommended to promote optimal performance, interpretation, and reporting of cases with an initial low to no ER staining result include establishing a laboratory-specific standard operating procedure describing additional steps used by the laboratory to confirm/adjudicate results. The status of controls should be reported for cases with 0% to 10% staining. Similar principles apply to PgR testing, which is used primarily for prognostic purposes in the setting of an ER-positive cancer. Testing of ductal carcinoma in situ (DCIS) for ER is recommended to determine potential benefit of endocrine therapies to reduce risk of future breast cancer, while testing DCIS for PgR is considered optional. Additional information can be found at www.asco.org/breast-cancer-guidelines .
dc.formatPrint-Electronic
dc.format.extent545 - 563
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectHumans
dc.subjectCarcinoma, Intraductal, Noninfiltrating
dc.subjectBreast Neoplasms
dc.subjectReceptors, Progesterone
dc.subjectEstrogens
dc.subjectPrognosis
dc.subjectImmunohistochemistry
dc.subjectMedical Oncology
dc.subjectPathology, Clinical
dc.subjectAmerican Medical Association
dc.subjectUnited States
dc.subjectFemale
dc.subjectPathologists
dc.titleEstrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.
dc.typeJournal Article
dcterms.dateAccepted2019-10-23
rioxxterms.versionofrecord10.5858/arpa.2019-0904-sa
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2020-05
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfArchives of pathology & laboratory medicine
pubs.issue5
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.publication-statusPublished
pubs.volume144
pubs.embargo.termsNo embargo
icr.researchteamEndocrinologyen_US
dc.contributor.icrauthorDowsett, Mitchen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record